Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics

Drug Profile

Research programme: glucocorticoid receptor II antagonists - Corcept Therapeutics

Alternative Names: CORT 112716; CORT 113083; CORT 122928

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corcept Therapeutics
  • Class
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alcoholism; Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer; Memory disorders; Muscular dystrophies; Obesity; Post-traumatic stress disorders; Prostate cancer
  • No development reported Psychiatric disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA (PO)
  • 30 Jan 2017 Preclinical trials in Prostate cancer in USA (PO) before January 2017
  • 02 Aug 2016 Corcept plans phase I trials for CORT 122928
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top